C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair

C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair

Retinoic acid receptor β2 (RARβ2) is an emerging therapeutic target for spinal cord injuries (SCIs) with a unique multimodal regenerative effect. We have developed a first-in-class RARβ agonist drug, C286, that modulates neuron-glial pathways to induce functional recovery in a rodent model of sensor...

Full description

Bibliographic Details
Main Authors: Maria B. Goncalves, Yue Wu, Earl Clarke, John Grist, Julien Moehlin, Marco Antonio Mendoza-Parra, Carl Hobbs, Barret Kalindjian, Henry Fok, Adrian P. Mander, Hana Hassanin, Daryl Bendel, Jörg Täubel, Tim Mant, Thomas Carlstedt, Julian Jack, Jonathan P. T. Corcoran
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-08-01
Series:Frontiers in Molecular Neuroscience
Subjects:
retinoic acid
drug
pathway analysis
nerve regeneration and repair
human data
Online Access:https://www.frontiersin.org/articles/10.3389/fnmol.2024.1411384/full

Internet

https://www.frontiersin.org/articles/10.3389/fnmol.2024.1411384/full

Similar Items